Predicting extensively drug-resistant Mycobacterium tuberculosis phenotypes with genetic mutations

Journal of Clinical Microbiology

Volumn 52, Issue 3, 2014, Pages 781-789

  Rodwell, Timothy C ^a   Valafar, Faramarz ^b   Douglas, James ^c   Qian, Lishi ^c   Garfein, Richard S ^a   Chawla, Ashu ^b   Torres, Jessica ^b   Zadorozhny, Victoria ^b   Kim, Min Soo ^b   Hoshide, Matt ^c   Catanzaro, Donald ^b   Jackson, Lynn ^a   Lin, Grace ^d   Desmond, Edward ^d   Rodrigues, Camilla ^e   Eisenach, Kathy ^f   Victor, Thomas C ^g   Ismail, Nazir ^h   Crudu, Valeru ⁱ   Gler, Maria Tarcela ^j   Catanzaro, Antonino ^a   more..

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b SAN DIEGO STATE UNIVERSITY   (United States)

^c UNIVERSITY OF HAWAII   (United States)

^d CALIFORNIA DEPARTMENT OF PUBLIC HEALTH   (United States)

^e P D HINDUJA NATIONAL HOSPITAL   (India)

^f UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^g STELLENBOSCH UNIVERSITY   (South Africa)

^h National Reference Laboratory for Tuberculosis   (South Africa)

ⁱ Microbiology and Morphology Laboratory   (Moldova)

^j Tropical Disease Foundation   (Philippines)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CAPREOMYCIN; DNA TOPOISOMERASE (ATP HYDROLYSING) A; DNA TOPOISOMERASE (ATP HYDROLYSING) B; ISONIAZID DERIVATIVE; KANAMYCIN; KATG PROTEIN; MOXIFLOXACIN; OFLOXACIN; RIFAMPICIN; RNA POLYMERASE BETA SUBUNIT;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; DIAGNOSTIC PROCEDURE; DNA EXTRACTION; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; GENE FREQUENCY; GENE MUTATION; GENE SEQUENCE; HUMAN; INDIA; MOLDOVA; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; PHENOTYPE; PHILIPPINES; PREDICTION; PRIORITY JOURNAL; PYROSEQUENCING; SENSITIVITY AND SPECIFICITY; SINGLE NUCLEOTIDE POLYMORPHISM; SOUTH AFRICA;

ANTITUBERCULAR AGENTS; BACTERIAL PROTEINS; DNA, BACTERIAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; GENOTYPE; HUMANS; INDIA; MICROBIAL SENSITIVITY TESTS; MOLDOVA; MOLECULAR DIAGNOSTIC TECHNIQUES; MYCOBACTERIUM TUBERCULOSIS; PHENOTYPE; PHILIPPINES; POINT MUTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS, DNA; SOUTH AFRICA;

EID: 84896707560     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.02701-13     Document Type: Article

References (44)

1. World Health Organization (WHO). 2012. Global tuberculosis report 2012. Report WHO/H TM/T B/2012.6. World Health Organization, Geneva, Switzerland. http://apps.who.int/iris/bitstream/10665/75938/1/9789241564502-eng.pdf.
2. World Health Organization (WHO). 2013. Global tuberculosis report 2013. Report WHO/HTM/TB/2013.11. World Health Organization, Geneva, Switzerland. http://apps.who.int/iris/bitstream/10665/91355/1/9789241564656-eng.pdf.
3. Shah NS, Richardson J, Moodley P, Moodley S, Babaria P, Ramtahal M, Heysell SK, Li X, Moll AP, Friedland G, Sturm AW, Gandhi NR. 2011. Increasing drug resistance in extensively drug-resistant tuberculosis, South Africa. Emerg. Infect. Dis. 17:510-513. http://dx.doi.org/10.3201/eid1703.101363.
4. Dharmadhikari AS, Basaraba RJ, Van Der Walt ML, Weyer K, Mphahlele M, Venter K, Jensen PA, First MW, Parsons S, McMurray DN, Orme IM, Nardell EA. 2011. Natural infection of guinea pigs exposed to patients with highly drug-resistant tuberculosis. Tuberculosis (Edinb.) 91: 329-338. http://dx.doi.org/10.1016/j.tube.2011.03.002.
5. Escombe AR, Moore DA, Gilman RH, Pan W, Navincopa M, Ticona E, Martínez C, Caviedes L, Sheen P, Gonzalez A, Noakes CJ, Friedland JS, Evans CA. 2008. The infectiousness of tuberculosis patients coinfected with HIV. PLoS Med. 5:e188. http://dx.doi.org/10.1371/journal.pmed.0050188.
6. Ling DI, Zwerling AA, Pai M. 2008. GenoType MTBDR assays for the diagnosis of multidrug-resistant tuberculosis: a meta-analysis. Eur. Respir. J. 32:1165-1174. http://dx.doi.org/10.1183/09031936.00061808.
7. Evans CA. 2011. GeneXpert - a game-changer for tuberculosis control? PLoS Med. 8:e1001064. http://dx.doi.org/10.1371/journal.pmed.1001064.
8. Meyer-Rath G, Schnippel K, Long L, MacLeod W, Sanne I, Stevens W, Pillay S, Pillay Y, Rosen S. 2012. The impact and cost of scaling up GeneXpert MTB/RIF in South Africa. PLoS One 7:e36966. http://dx.doi.org/10.1371/journal.pone. 0036966.
9. World Health Organization (WHO). 2008. Molecular line probe assays for rapid screening of patients at risk of multi-drug resistant tuberculosis (MDR-TB): policy statement. World Health Organization, Geneva, Switzerland. http://www.who.int/tb/features-archive/policy-statement.pdf.
10. World Health Organization (WHO). 2013. The use of molecular line probe assay for the detection of resistance to second-line anti-tuberculosis drugs. Expert group meeting report. World Health Organization, Geneva, Switzerland. http://apps.who.int/iris/bitstream/10665/78099/1/WHO-HTM-TB-2013.01.eng.pdf.
11. Siddiqi SH, Rüsch-Gerdes S. 2006. MGIT procedure manual: for Bactec MGIT 960 TB system. FIND Diagnostics, Geneva, Switzerland. http://www. finddiagnostics.org/export/sites/default/resource-centre/find-documentation/ pdfs/mgit-manual-nov-2007.pdf.
12. World Health Organization (WHO). 2008. Policy guidance on drugsusceptibility testing (DST) of second-line antituberculosis drugs. Report WHO/HTM/TB/2008.392. World Health Organization, Geneva, Switzerland. http://whqlibdoc.who.int/hq/2008/WHO-HTM-TB-2008.392-eng.pdf.
13. Rodrigues C, Jani J, Shenai S, Thakkar P, Siddiqi S, Mehta A. 2008. Drug susceptibility testing of Mycobacterium tuberculosis against secondline drugs using the Bactec MGIT 960 system. Int. J. Tuberc. Lung Dis. 12:1449-1455.
14. Georghiou SB, Magana M, Garfein RS, Catanzaro DG, Catanzaro A, Rodwell TC. 2012. Evaluation of genetic mutations associated with Mycobacterium tuberculosis resistance to amikacin, kanamycin and capreomycin: a systematic review. PLoS One 7:e33275. http://dx.doi.org/10.1371/journal.pone.0033275.
15. Sandgren A, Strong M, Muthukrishnan P, Weiner BK, Church GM, Murray MB. 2009. Tuberculosis drug resistance mutation database. PLoS Med. 6:0132-0136. http://dx.doi.org/10.1371/journal.pmed.1000002.
16. Maruri F, Sterling TR, Kaiga AW, Blackman A, van der Heijden YF, Mayer C, Cambau E, Aubry A. 2012. A systematic review of gyrase mutations associated with fluoroquinolone-resistant Mycobacterium tuberculosis and a proposed gyrase numbering system. J. Antimicrob. Chemother.67:819-831. http://dx.doi.org/10. 1093/jac/dkr566.
17. Riska PF, Jacobs WR, Jr, Alland D. 2000. Molecular determinants of drug resistance in tuberculosis. Int. J. Tuberc. Lung Dis. 4(2 Suppl 1):S4-S10. (Pubitemid 30121046)
18. van Helden PD, Victor TC, Warren RM, van Helden EG. 2001. Isolation of DNA from Mycobacterium tuberculosis, p 19-30. In Parish T, StokerNG (ed), Mycobacterium tuberculosis protocols, vol 54. Humana Press, Totowa, NJ.
19. Lin G, Rodwell TC, Victor TC, Rider EC, Pham L, Catanzaro A, Desmond E. 27 November 2013. Pyrosequencing for rapid detection of extensively drug-resistant tuberculosis in clinical isolates and clinical specimens J. Clin. Microbiol. http://dx.doi.org/10.1128/JCM.01821-13.
20. Engström A, Morcillo N, Imperiale B, Hoffner SE, Jureen P. 2012. Detection of first-and second-line drug resistance in Mycobacterium tuberculosis clinical isolates by pyrosequencing. J. Clin. Microbiol. 50:2026-2033. http://dx.doi.org/10.1128/JCM.06664-11.
21. Newcombe RG. 1998. Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat. Med. 17:857-872. http://dx.doi.org/10.1002/(SICI)1097-0258(19980430)17:8-857::AID-SIM777-3.0. CO;2-E. (Pubitemid 28185165)
22. Vollset SE. 1993. Confidence intervals for a binomial proportion. Stat. Med. 12:809-824. http://dx.doi.org/10.1002/sim.4780120902. (Pubitemid 23162483)
23. Engström A, Perskvist N, Werngren J, Hoffner SE, Juréen P. 2011. Comparison of clinical isolates and in vitro selected mutants reveals that tlyA is not a sensitive genetic marker for capreomycin resistance in Mycobacterium tuberculosis. J. Antimicrob. Chemother. 66:1247-1254. http://dx.doi.org/10.1093/jac/dkr109.
24. Valvatne H, Syre H, Kross M, Stavrum R, Ti T, Phyu S, Grewal HM. 2009. Isoniazid and rifampicin resistance-associated mutations in Mycobacterium tuberculosis isolates from Yangon, Myanmar: implications for rapid molecular testing. J. Antimicrob. Chemother. 64:694-701. http://dx.doi.org/10.1093/jac/ dkp292.
25. Cade CE, Dlouhy AC, Medzihradszky KF, Salas-Castillo SP, Ghiladi RA. 2010. Isoniazid-resistance conferring mutations in Mycobacterium tuberculosis KatG: catalase, peroxidase, and INH-NADH adduct formation activities. Protein Sci. 19:458-474. http://dx.doi.org/10.1002/pro.324.
26. Laurenzo D, Mousa SA. 2011. Mechanisms of drug resistance in Mycobacterium tuberculosis and current status of rapid molecular diagnostic testing. Acta Trop. 119:5-10. http://dx.doi.org/10.1016/j.actatropica.2011.04. 008.
27. Rosales-Klintz S, Juréen P, Zalutskayae A, Skrahina A, Xu B, Hu Y, Pineda-Garcia L, Merza MA, Muntean I, Bwanga F, Joloba M, Hoffner SE. 2012. Drug resistance-related mutations in multidrug-resistant Mycobacterium tuberculosis isolates from diverse geographical regions. Int. J. Myco. 1:124-130. http://dx.doi.org/10.1016/j.ijmyco.2012.08.002.
28. Chang KC, Yew WW, Zhang Y. 2009. A systematic review of rapid drug susceptibility tests for multidrug-resistant tuberculosis using rifampin resistance as a surrogate. Expert Opin. Med. Diagn. 3:99-122. http://dx.doi.org/10.1517/17530050802665694.
29. Nebenzahl-Guimaraes H, Jacobson KR, Farhat MR, Murray MB. 20 September 2013. Systematic review of allelic exchange experiments aimed at identifying mutations that confer drug resistance in Mycobacterium tuberculosis. J. Antimicrob. Chemother. http://dx.doi.org/10.1093/jac/dkt358.
30. World Health Organization (WHO). 2012. Rapid implementation of the Xpert MTB/RIF diagnostic test: technical and operational 'how-to' practical considerations. Report WHO/HTM/TB/2011.2. World Health Organization, Geneva, Switzerland. http://whqlibdoc.who.int/publications/2011/9789241501569-eng.pdf.
31. Rigouts L, Gumusboga M, de Rijk WB, Nduwamahoro E, Uwizeye C, de Jong B, Van Deun A. 2013. Rifampin resistance missed in automated liquid culture system for Mycobacterium tuberculosis isolates with specific rpoB mutations. J. Clin. Microbiol. 51:2641-2645. http://dx.doi.org/10.1128/JCM.02741-12.
32. Van Deun A, Aung KJ, Bola V, Lebeke R, Hossain MA, de Rijk WB, Rigouts L, Gumusboga A, Torrea G, de Jong BC. 2013. Rifampin drug resistance tests for tuberculosis: challenging the gold standard. J. Clin. Microbiol. 51:2633-2640. http://dx.doi.org/10.1128/JCM.00553-13.
33. Van Deun A, Barrera L, Bastian I, Fattorini L, Hoffmann H, Kam KM, Rigouts L, Rüsch-Gerdes S, Wright A. 2009. Mycobacterium tuberculosis strains with highly discordant rifampin susceptibility test results. J. Clin. Microbiol. 47:3501-3506. http://dx.doi.org/10.1128/JCM.01209-09.
34. Williamson DA, Roberts SA, Bower JE, Vaughan R, Newton S, Lowe O, Lewis CA, Freeman JT. 2012. Clinical failures associated with rpoB mutations in phenotypically occult multidrug-resistant Mycobacterium tuberculosis. Int. J. Tuberc. Lung Dis. 16:216-220. http://dx.doi.org/10.5588/ijtld.11.0178.
35. Ho J, Jelfs P, Sintchencko V. 2013. Phenotypically occult multidrugresistant Mycobacterium tuberculosis: dilemmas in diagnosis and treatment. J. Antimicrob. Chemother. 68:2915-2920. http://dx.doi.org/10.1093/ jac/dkt284.
36. van Ingen J, Aarnoutse R, de Vries G, Boeree MJ, van Soolingen D. 2011. Low-level rifampicin-resistant Mycobacterium tuberculosis strains raise a new therapeutic challenge. Int. J. Tuberc. Lung Dis. 15:990-992. http://dx.doi.org/10.5588/ijtld.10.0127.
37. Horne DJ, Pinto LM, Arentz M, Lin SYG, Desmond E, Flores LL, Steingart KR, Minion J. 2013. Diagnostic accuracy and reproducibility of WHO-endorsed phenotypic drug susceptibility testing methods for firstline and second-line antituberculosis drugs. J. Clin. Microbiol. 51:393-401. http://dx.doi.org/10. 1128/JCM.02724-12.
38. Ängeby K, Juréen P, Kahlmeter G, Hoffner SE, Schön T. 2012. Challenging a dogma: antimicrobial susceptibility testing breakpoints for Mycobacterium tuberculosis. Bull. World Health Organ. 90:693-698. http://dx.doi.org/10.2471/BLT.11.096644.
39. Juréen P, Angeby K, Sturegård E, Chryssanthou E, Giske CG, Werngren J, Nordvall M, Johansson A, Kahlmeter G, Hoffner S, Schön T. 2010. Wild-type MIC distributions for aminoglycoside and cyclic polypeptide antibiotics used for treatment of Mycobacterium tuberculosis infections. J. Clin. Microbiol. 48:1853-1858. http://dx.doi.org/10.1128/JCM.00240-10.
40. Campbell PJ, Morlock GP, Sikes RD, Dalton TL, Metchock B, Starks AM, Hooks DP, Cowan LS, Plikaytis BB, Posey JE. 2011. Molecular detection of mutations associated with first-and second-line drug resistance compared with conventional drug susceptibility testing of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 55:2032-2041. http://dx.doi.org/10.1128/AAC.01550- 10.
41. Gikalo MB, Nosova EY, Krylova LY, Moroz AM. 2012. The role of eis mutations in the development of kanamycin resistance in Mycobacterium tuberculosis isolates from the Moscow region. J. Antimicrob. Chemother. 67:2107-2109. http://dx.doi.org/10.1093/jac/dks178.
42. Tukvadze N, Kempker R, Aspindzelahvili R, Bablishvili N, Kipiani M, Blumberg H. 2012. Abstr.S1-S450. 43rd World Conference on Lung Health of the International Union Against Tuberculosis and Lung Disease, International Union Against Tuberculosis and Lung Disease, Kuala Lumpur, Malaysia, 13 to 17 November 2012.
43. García-Sierra N, Lacoma A, Prat C, Haba L, Maldonado J, Ruiz-Manzano J, Gavin P, Samper S, Ausina V, Domínguez J. 2011. Pyrosequencing for rapid molecular detection of rifampin and isoniazid resistance in Mycobacterium tuberculosis strains and clinical specimens. J. Clin. Microbiol. 49:3683-3686. http://dx.doi.org/10.1128/JCM.01239-11.
44. Riley RL, Mills CC, Nyka W, Weinstock N, Storey PB, Sultan LU, Riley MC, Wells WF. 1959. Aerial dissemination of pulmonary tuberculosis: a two-year study of contagion in a tuberculosis ward. Am. J. Hyg. 70:185-196